Feldman EJ et al. – Single induction response occurred over a 2.3–fold range of doses indicating that CPX–351 may be useful at high doses for patients suitable for intensive chemotherapy and at reduced doses for patients at increased risk of treatment–related mortality. The unique pharmacologic features of CPX–351 contribute to its promising antileukemic efficacy.
Register now to view all the MDLinx contents (FREE)!
Login
Sponsor
Stay current - Media Tool
♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦
♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦
Close
Sponsor